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BACKGROUND: A possible increase in the incidence of venous thromboembolic events has been reported among users of third
generation oral contraceptives. The objective of this study was to evaluate the effect of a low dose oral contraceptive (15 µg ethinyl
estradiol/60 µg gestodene) on the venous endothelial function of healthy young women.
METHODS: Prospective case control study using the dorsal hand vein technique. Venous endothelial function was evaluated at
baseline and after 4 months in the oral contraceptive users group (11 women) and in a control group (9 women). After preconstriction
of the vein with phenylephrine, dose-response curves for acetylcholine and sodium nitroprusside were constructed.
RESULTS: In the contraceptive users group, a reduction occurred in the maximum venodilation response to acetylcholine and
sodium nitroprusside after 4 months of oral contraceptive use, but this difference was not statistically significant (P > 0.05). No
significant changes were detected in maximum venodilation responses to acetylcholine and sodium nitroprusside at the 4-month
time point in the control group.
CONCLUSION: This study found no significant impairment of endothelium-dependent or independent venodilation in healthy
young women following oral contraceptive use. Further studies are necessary using the same methodology in a larger sample over
a longer follow-up period.
KEYWORDS: Oral contraceptives. Venous endothelium. Venous thrombosis.
INTRODUCTION
Millions of women of reproductive age around the
world use oral contraceptives (OC).1 However, adverse ef-
fects associated with oral contraceptive use, notably the in-
creased risk of a venous thromboembolic event and of car-
diovascular diseases, such as strokes and myocardial
infarctions, were reported soon after the introduction of this
contraceptive method in the early 1960s.2,3
New hormonal formulations and preparations have been
developed in an attempt to reduce these adverse effects.
First, the estrogen content of oral contraceptives was re-
duced, and later, newer progestins, such as desogestrel,
norgestimate, and gestodene, were developed, giving rise
to the third-generation oral contraceptives. In the mid-
1990s, however, a few reports suggested a possible increase
in the incidence of venous thrombosis among users of oral
contraceptives containing these new progestins.4,5 These
publications were followed by several papers either con-
firming or disputing these findings, and by a number of
studies comparing the hemostatic effects of second- and
third-generation oral contraceptives.
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Although the two generations of oral contraceptives
may indeed have slightly different risks, not only with re-
spect to venous thromboembolic event but also stroke and
myocardial infarction, the etiology of these differences is
unclear. An increase in the incidence of venous thrombo-
sis in oral contraceptives users may, at least partially, be
due to impairment of endothelial function.
Endothelial dysfunction is recognized as an initial step
in the development of cardiovascular disease and venous
thromboembolism. Endothelial cells mediate hemostasis by
regulating the balance between procoagulant and anticoagu-
lant factors, proadhesive and antiadhesive forces, vasocon-
striction and vasodilation, and a variety of other functions.
The vascular endothelium produces a variety of vasoactive
substances, including nitric oxide (NO), endothelin-1, and
prostacyclin, that influence thrombogenicity and the vaso-
motor response of underlying smooth muscle cells. Signifi-
cant alterations in the production of these endothelium-de-
rived factors have been found in venous thrombosis.6
Nitric oxide (NO) is an endothelium-derived, vasoac-
tive substance that is generated by enzymatic oxidation of
the amino acid L-arginine into L-citrulline by the action
of NO-synthase. Among the various functions of NO, 2 are
of major importance in the cardiovascular system: its
vasodilatory capacity and its inhibitory effect on platelet
aggregation and adhesion. L-arginine modulates the throm-
botic process and inhibits platelet aggregation.6 Endogenous
NO has been shown to protect against thromboembolism
in venules,7 while L-arginine improves endothelial
vasoreactivity and reduces thrombogenicity after throm-
bolysis in experimental deep venous thrombosis.8
There are various techniques available for the evalua-
tion of peripheral endothelial function; however, the
noninvasive methods have not yet been adequately stand-
ardized despite their widespread use in clinical research.9
Plethysmography with intra-arterial injections of acetylcho-
line has been used to measure vessel reactivity due to NO
release, but this technique requires intra-arterial puncture,
which makes it unsuitable for serial studies. Moreover, this
technique evaluates the arterial system, whose dysfunction
is related to atherosclerosis and arterial thrombosis, not to
venous thromboembolic disease in young women.
Dorsal hand veins have also been shown to release en-
dothelial NO when they are precontracted with norepine-
phrine and then stimulated with an agonist such as acetyl-
choline or bradykinin.10–13 The dorsal hand vein technique
is a sensitive tool for assessing the in-vivo effects of drugs
on the peripheral veins of human subjects. This method is
currently being used by various groups of investigators, in-
cluding ours, to evaluate venous endothelial function in a
variety of pathophysiologic conditions.14–20
This prospective, case-control study was designed to
investigate endothelium-dependent and -independent va-
sodilation in the venous endothelium of oral contraceptive
users compared to a control group of women not currently
using any hormonal contraceptive method (intrauterine de-
vice users). The objective of the study was to evaluate
whether any changes occur in vasodilatory responses fol-
lowing initiation of oral contraceptive use.
This technique has not previously been used in studies
of vasomotion in healthy young oral contraceptive users.
MATERIALS AND METHODS
Study population
A prospective case control study was carried out in 2
groups of women aged 18 through 35 years, recruited from
the family planning clinic of the Department of Gynecology
at the University of São Paulo’s teaching hospital.
The sample comprised 11 women who were about to
initiate combined oral contraceptive use, and 9 women not
currently using any hormonal contraceptive method, com-
prising the control group. Women in the control group were
all current users of an intrauterine device. The contracep-
tive mechanism of action of the copper intrauterine device
involves no hormonal or hemodynamic effects, and the de-
vice is a highly effective method of birth control.21
Exclusion criteria for both groups comprised the fol-
lowing: age > 35 years, hypercholesterolemia, hyperten-
sion, diabetes, impaired renal function, history of smok-
ing, obesity (body mass index > 28), positive pregnancy
test, and use of any hormonal contraception in the preced-
ing 12 months.
The study was approved by the Internal Review Board
of the institution, and all participants gave their signed, in-
formed consent prior to enrollment.
The venous endothelial function of women in both
groups was evaluated using the dorsal hand vein technique
(DHVT). In the study group, venous endothelial function
was evaluated prior to (baseline) and after 4 months of oral
contraceptive use. In the control group, it was evaluated at
admission to the study and again 4 months later.
The oral contraceptive selected for use in this study con-
tained a combination of 15 µg ethinylestradiol and 60 µg
gestodene. Women in the study group were provided with
4 cycles of the medication and instructed to use the oral
contraceptive for 24 days followed by 4 medication-free
days, for 4 consecutive months.
Because previous studies have shown a negative corre-
lation between abnormal levels of triglycerides, cholesterol
and fractions, and endothelial function, blood was drawn
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for evaluation of lipids (triglycerides, total cholesterol, and
fractions) and glucose in both groups at the 2 time points
of the venous endothelial function evaluation.17,22–24
Study Protocol
Dorsal hand vein technique. The dorsal hand vein
compliance technique was performed as described previ-
ously.11–14 This technique has the advantage of allowing the
infusion of very small amounts of vasoactive substances,
thus avoiding potentially confounding systemic
hemodynamic effects.15–20
Briefly, subjects lay supine in a temperature-controlled
room (24 ± 2 °C). One arm was placed on a vacuum cush-
ion (Germa Protec, Germa AB, Kristianstad, Sweden) above
heart level, sloping upwards at an angle of 30 degrees from
the horizontal plane to allow veins to be completely emp-
tied. A suitable, large superficial hand vein with no appar-
ent tributaries in the immediate area of examination was
chosen. A 25-gauge butterfly needle was then inserted into
the selected dorsal hand vein, and 0.9% saline was infused
for at least 60 min at a constant infusion rate of 0.3 mL/
min. A small tripod holding a linear variable differential
transformer (LVDT, Model 100 MHR, Schaevitz, Lucas
Control System Products, Hampton, VA, USA), was
mounted over the selected vein at a distance of 10 mm
downstream from the tip of the needle. The linear range
of the LVDT core movement was ± 4 mm. The position of
the core was recorded on a strip-chart recorder. The diam-
eter of the vein was measured by recording the displace-
ment of the freely movable core of the LVDT, which is lin-
early related to voltage output for movements of ± 4 mm
(ATA 101, Schaevitz Engineering, Pennsauken, NJ, USA)
when the pressure in the cuff placed around the upper arm
was inflated to 40 mm Hg. Dilation of the vein at baseline
between 40 and 60 min of saline infusion was defined as
100%. Due to the low venous tone present under these con-
ditions, venodilator effects can be quantified only in
preconstricted vessels. Phenylephrine, a selective a1-
adrenoceptor agonist, was used to preconstrict the hand
veins. The dose of phenylephrine able to produce 80% con-
striction was used (ED80) and for purposes of subsequent
calculations, this dose rate and this level of constriction
were defined as 0% dilatation. The vasodilatory effects ex-
amined in this study were calculated and expressed as a
percentage ranging from 0% to 100% dilatation. This same
dose of phenylephrine (46-2500 ng/min) was then infused
at a constant rate producing stable venoconstriction for the
duration of the experiment.
After preconstriction of the vein with phenylephrine,
dose response curves for acetylcholine (0.36-3600 ng/min)
and sodium nitroprusside (50-1000 ng/min) were con-
structed, with infusion rates of 5 and 3, respectively, in both
the oral contraceptive and control groups.
Systolic and diastolic blood pressure was measured us-
ing a mercury sphygmomanometer, and heart rate was meas-
ured using the radial artery pulse. All measurements were
obtained both before and after each experimental phase.
Statistical analysis. Wilcoxon’s nonparametric test for
paired samples was used to compare changes in maximum
venodilation (Emax) of acetylcholine and sodium nitroprus-
side in each group. Other biochemical, physical, and
hemodynamic parameters were assessed using analysis of
variance (ANOVA). Significance level was established at
5% for all statistical analyses. Data are presented as de-
scriptive tables with respective means and standard devia-
tions.
RESULTS
Clinical and laboratory characteristics. The clinical
and laboratory data of patients in this study are shown in
Table 1. There were no significant differences in weight
and body mass index between groups, and there were no
changes between admission values and those obtained at
the 4-month evaluation for these parameters.
Although there was a significant difference in age be-
tween the 2 groups, all patients in the study were under
35 years of age. Because previous studies have shown that
the principal deleterious effects of aging on endothelial
function occur predominantly after 40 years of age,25 this
difference should have had no impact on the results found
in this study with respect to endothelial function.
Table 1 - Clinical and laboratory data of study and control
groups
Group
Study Group Control Group
Variable n = 11 n = 9 P
Mean SD Mean SD
Age (years) 24.77 4.11 32.11 7.91 0.030*
Weight (kg) 58.38 6.30 59.67 4.61 0.393
Height (m) 1.59 0.04 1.60 0.06 0.556
BMI (kg/m2) 23.07 3.11 23.33 2.20 0.512
Glucose (mg/dL) 82.38 8.93 87.11 5.62 0.357
Total Cholesterol (mg/dL) 165.69 29.90 166.11 37.71 0.854
LDL (mg/dL) 93.46 23.29 96.60 12.63 0.939
HDL (mg/dL) 55.08 13.18 53.38 24.32 0.198
Triglycerides (mg/dL) 85.62 25.12 82.44 31.24 0.521
SBP (mm Hg) 108 4.3 111.8 3.35 0.456
DBP (mm Hg) 72.5 3.44 73 2.06 0.632
Values are expressed as mean ± standard deviation. BMI: body mass index,
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP: systolic
blood pressure, DBP: diastolic blood pressure (* P < 0.05, significant P
value).
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Levels of glucose, triglycerides, total cholesterol, and
fractions were normal, according to the guidelines of the
National Cholesterol Education Program – Adult Treatment
Panel (NCEP-ATP III), in both groups at both time points
of the study.26
Hemodynamic parameters. Heart rate and systolic and
diastolic blood pressure were within the normal range in
both groups at baseline. No significant change in these pa-
rameters was found after 4 months. Infusion of acetylcho-
line and sodium nitroprusside during DHVT resulted in no
systemic hemodynamic changes (data not shown).
Endothelium-dependent venodilation assessed by
DHVT (Table 2). In the study group, the maximum ve-
nous dilation (Emax) with acetylcholine (endothelium–de-
pendent vasodilation) was 68.08% ± 51.23% (mean ± SD)
at baseline. After 4 months of oral contraceptive use, Emax
decreased to 58.00% ± 34.46%. This change was not sig-
nificant (P > 0.05).
In the control group, there were no significant changes
in maximum venous dilation (Emax) with acetylcholine
when comparing baseline (59.33% ± 38.76%) and 4-month
values (75.89% ± 60 %) (P > 0.05).
Endothelium-independent venodilation as assessed by
DHVT (Table 2). In the study group, maximum venous di-
lation (Emax) with sodium nitroprusside (endothelium–in-
dependent vasodilation) was 164.83% ± 79.42% (mean ±
SD) at baseline. After 4 months of oral contraceptive use,
Emax decreased to 115.67% ± 45.44. This decrease in
venodilation was not significant (P > 0.05). In the control
group, no significant changes occurred in maximum venous
dilation (Emax) with sodium nitroprusside (endothelium–
independent vasodilation) when comparing baseline
(135.56% ± 48.76 %) and 4- month values (130.67% ±
56.82 %) (P > 0.05).
DISCUSSION
This is the first study evaluating endothelium-depend-
ent and independent responses in the venous system by
DHVT in healthy young women following combined oral
contraceptive use. Most studies addressing endothelial func-
tion and hormone therapy in women have been carried out
in an older population, mostly in postmenopausal women
using natural estrogens. Moreover, those studies were car-
ried out on the arterial system.
Our results showed a reduction in endothelial depend-
ent and independent venodilation after oral contraceptive
use, but without reaching statistical significance, probably
due to large intersubject variability in vasodilation re-
sponses to acetylcholine and sodium nitroprusside.
Intersubject variability in vascular responses, mainly to ace-
tylcholine has also been observed in many studies with
DHVT.10,17,19,20 However, as the variability in our results was
larger than in other studies with the same technique, an in-
crease in our sample size is necessary.
Oral contraception is associated with an increased risk
of morbid cardiovascular events such as stroke, myocardial
infarction, deep vein thrombosis, and venous thromboem-
bolism,27,28 especially among women who have concomi-
tant risk factors such as smoking.29,30 Since 1995, several
observational studies have reported an increased risk (ap-
proximately 2-fold) of nonfatal venous thromboembolism
associated with third-generation oral contraceptives.31,32
Many studies have evaluated the effects of second- and
third-generation oral contraceptives on hemostasis in an at-
tempt to explain the apparent differences.33–36 Estrogen has
well-defined effects on hemostasis. It increases fibrinogen
levels; coagulation factors VII, VIII, and X; and plasmino-
gen. Its use is associated with lower levels of antithrombin
III, protein S, and plasminogen activator inhibitor. Use of
oral contraceptives leads to decreased activated protein C
resistance (APC resistance). The net effect of these
procoagulant and anticoagulant changes is a small increase
in coagulation.28
It must be emphasized, however, that the endothelium
plays a major role as the principal regulator of hemostasis.
First, vascular wall integrity is now known to consist of
both structural and functional components. There is no
Table 2 - Maximum venous dilation (Emax) with acetylcholine (ACH) and with nitroprusside (NPS) at baseline and after
four months, in the study and control groups
Group
Measurement Case Control
Mean SD Median Range N p Mean SD Median Range n P
ACH (baseline) 68.08 51.23 62.5 195.0 11 0.530 59.33 38.77 54.0 132.0 9 0.767
ACH (4 months) 58.00 34.46 63.5 119.0 11 75.89 60.21 42.0 176.0 9
NPS (baseline) 164.83 79.42 159.0 237.0 11 0.117 135.56 48.76 124.0 171.0 9 0.500
NPS (4 months) 115.67 45.44 105.5 142.0 11 130.67 56.83 124.0 202.0 9
Data are expressed as mean values ± standard deviation (SD)
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question that physical injury to the vascular wall is a pow-
erful trigger of the coagulation mechanism. However, func-
tional disruption of the intact endothelium represents a far
more common catalyst for the prothrombotic state. Sec-
ondly, blood flow stasis is a consequence not only of an
increase in hydrostatic pressure but also of an imbalance
in the endothelial- and vascular smooth muscle cell-derived
vasoregulatory factors. Endothelial cells release a number
of substances, including endothelial nitric oxide synthase
(eNOS), prostacyclin, plasminogen activator factor (PAF),
and endothelin-1, that regulate the tone of the blood ves-
sel wall. Because the luminal diameter is a critical deter-
minant of blood flow, the net balance of vasodilatory and
vasoconstricting molecules has an important effect on lo-
cal hemostatic balance. Finally, alterations in the levels of
circulating procoagulants and/or anticoagulants are now
known to have unique effects on the hemostatic balance
of local vascular beds.6
There is evidence that synthetic sex steroids may have
different effects on endothelial cells from those of endog-
enous steroids, which are suppressed during the use of oral
contraceptives.37–39 In contrast to the effects of physiologic
estrogens, which have been shown to preserve endothelial
function, one of the possible mechanisms linked to this in-
crease in venous thromboembolism and cardiovascular dis-
ease in oral contraceptive users may be endothelial dys-
function.
There are several methods, both experimental and clini-
cal, of evaluating endothelial function. Most involve the
arterial system, the dysfunction of which is associated with
the development of atherosclerosis, hypertension, and ar-
terial thrombosis. Some clinical studies rely on circulat-
ing levels of activation markers as an indicator of endothe-
lial cell dysfunction. Mutunga et al, 2001, for example,
have developed a method of detecting circulating endothe-
lial cells (EC) that provides direct evidence of EC shed-
ding in human sepsis.40 However, these methods do not pro-
vide any information about the site of disease involvement.
Moreover, high levels of activation markers do not indi-
cate whether endothelial cell dysfunction is a cause or con-
sequence of the underlying disorder. This type of evalua-
tion is complicated by the fact that many stimuli such as
exercise and infections can change their release.6,9
The DHVT is a less invasive method and allows direct
assessment of the influence of many pathophysiological
conditions related to venous endothelial dysfunction, such
as thromboembolic disease. Despite the limitations of be-
ing performed in the superior limb, which leads to an un-
derestimation of the role of hydrostatic pressure in physi-
opathology of thrombosis, the DHVT is currently the only
method available for assessing venous endothelial function
in humans. Methods performed in the inferior limbs, like
the occlusion plethysmographic technique, although assess-
ing the limb volume change in response to venous filling,
measure whole limb compliance and do not discriminate
between the venous and soft tissue elements involved in
limb compliance. Another important limitation of the oc-
clusion plethysmographic method is that there is no direct
measure of venous pressure and venous endothelial func-
tion after direct pharmacological stimuli.41
A few studies have recently been published on the ef-
fects of OC on endothelial function. However, because a
wide variety of different techniques were used to evaluate
endothelial function in those studies, such as imaging tech-
niques (magnetic resonance, Doppler), in-vitro cultures,
serum markers of endothelial dysfunction, and brachial ar-
tery plethysmography, a comparison of the results is not
possible.42–47 Similarly, they cannot be compared with the
results of our study, because we used an in-vivo, direct
evaluation of venous endothelial function.
For example, in one of those studies, Stefan et al,44
analyzed endothelial function using forearm plethysmog-
raphy in women taking OC, and compared them to a con-
trol group in a cross sectional study. These investigators
found no significant differences in endothelium-dependent
or endothelium-independent vasodilatation responses be-
tween the 2 groups. In contrast, NG-monomethyl-L-ar-
ginine infusion induced a significant decrease in blood flow
in women using OC compared to the control group (–26%
± 3% vs –14% ± 5%; P = 0.009). The authors concluded
that although NO bioavailability remained unaffected in a
group of premenopausal women receiving oral contracep-
tives, basal NO production and release appeared to be en-
hanced by oral contraceptive use.44 Virdis et al 45 also stud-
ied the effect of a third-generation oral contraceptive on
endothelial function using forearm arterial plethysmogra-
phy in healthy young women. Endothelial function re-
mained unchanged after 6 months of oral contraceptive use
(30 µg ethinylestradiol + 75 µg gestodene daily) despite
the unfavorable changes in the lipid profile that occurred
during the study. The authors speculated that the adverse
effects of increased lipid levels were counterbalanced by
the assumed beneficial influences of the oestrogen com-
ponent. Their assumption implies a neutral effect of the
gestodene component. However, data on the influence of
progestogens on endothelial function are inconsistent. In
some studies, the favorable effect of estrogen on endothe-
lial function was unchanged by progestogens.46 Other in-
vestigators, such as Sorensen et al,47 evaluated the effects
of progestogens on endothelial function using cardiovas-
cular magnetic resonance and found that progestogens re-
duced or offset the estrogen-mediated response.
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However, those studies evaluated the arterial endothe-
lium, the dysfunction of which is associated with the devel-
opment of atherosclerosis, arterial thrombosis, and hyperten-
sion. Since endothelial cells play an important role in
hemostasis, we elected to use DHVT to evaluate the venous
system instead of the arterial system to investigate the in-
fluence of an OC on venous endothelial function. Our goal
was to investigate whether venous endothelium dysfunction
is one of the possible mechanisms of the increased incidence
of venous thromboembolic event in healthy young oral con-
traceptive users. Our results show no significant difference
in endothelium-dependent or endothelium-independent
venodilation following oral contraceptive use.
Although NO-dependent vasodilatation is an important
component of endothelial function related to increased ve-
nous thromboembolism and cardiovascular risk in oral con-
traceptive users, it is not the only one, and it may not be the
only mechanism by which oral contraceptive use increases
the risk of venous thromboembolism. The intact endothe-
lium also exerts antithrombotic and antiinflammatory effects
that were not evaluated and were not detected in the assess-
ment of NO-dependent vasodilatation.
CONCLUSION
Although the sample size was limited, this is the first
study in which the association between oral contraceptive
use and venous endothelial function has been evaluated in
vivo. Our results indicate no significant impairment of en-
dothelium-dependent or independent venodilation in
healthy young women following initiation of oral contra-
ceptive use. Since there was a large intersubject variation
in the results obtained with the technique used in this study,
further studies using the same method should be carried
out in a larger group of patients over a longer follow-up
period.
RESUMO
Giribela CRG, Rubira MC, Melo NR de, Plentz RDM,
Angelis K de, Moreno H, Consolim-Colombo FM. Efeito
de um anticoncepcional hormonal oral de baixa dose na
função endotelial venosa em mulheres jovens saudáveis:
resultados preliminares. Clinics. 2007;62(2):151-8.
Um aumento no risco de tromboembolismo venoso têm
sido descrito em usuárias de anticoncepcionais hormonais
oral de terceira geração.
OBJETIVO: Avaliar o efeito de um anticoncepcional com-
binado hormonal oral de baixa dose (15 µg etinil estradiol/
60 µg gestodeno) na função endotelial venosa de mulhe-
res jovens saudáveis.
MÉTODOS: Realizou-se um estudo caso-controle
prospectivo em vinte mulheres jovens saudáveis que foram
avaliadas pela técnica da complascência venosa. A função
endotelial venosa foi avaliada em um momento basal e após
4 meses no grupo das usuárias de anticoncepcional oral (11
mulheres) e em um grupo controle (9 mulheres). Foram
construídas curvas dose resposta para acetilcolina e
nitroprussiato de sódio após a pré-constrição da veia com
fenilefrina.
RESULTADOS: No grupo de usuárias de anticoncepcio-
nal combinado hormonal oral houve diminuição da
venodilatação máxima em resposta a acetilcolina e
nitroprussiato de sódio, porém esta mudança não foi esta-
tisticamente significante (p> 0,05). No grupo controle não
foram detectadas mudanças significantes na venodilatação
máxima, em resposta a acetilcolina e nitroprussiato de sódio
no intervalo de 4 meses.
CONCLUSÃO: Este estudo não observou redução
significante da venodilatação endotélio dependente e inde-
pendente após os uso de anticoncepcional combinado
hormonal oral. Mais estudos são necessários utilizando a
mesma metodologia em uma amostra maior e com maior
tempo de seguimento.
UNITERMOS: Anticoncepcional Combinado Hormonal
Oral/ Endotélio Venoso/ Trombose Venosa
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